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FIGURE 3. EML4–ALK fusion gene 
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hybridization/reverse transcriptase-
polymerase chain reaction/next 
generation sequencer).
carcinoma harboring the EML4–ALK 
rearrangement.
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To the Editor:
Malignant granular cell tumors 
(GCTs) are extremely rare. We read that 
De Luca et al1 reported a giant malignant 
GCT of posterior mediastinum. In this 
letter, we would like to share our experi-
ence of a case with malignant pulmonary 
GCT and explore the underlying mecha-
nisms by next generation sequencing.
A 63-year-old woman presented 
with chronic cough for several months. 
An enhanced chest computed tomogra-
phy indicated a large solitary mass in the 
lower lobe of left lung, approximately 
14 × 10 × 9 cm in size (Fig. 1). Physical 
examination, laboratory evaluation, and 
other radiological tests revealed no sig-
nificant abnormalities, with the excep-
tion of high expression of NSE (67.41 
μg/liter, range, 0–16.3 μg/liter). A bron-
choscopic biopsy was performed from 
the basal stem of left lower lobe, and the 
diagnosis of GCT was considered given 
that the immunohistochemistry staining 
of S-100 (+), Vimentin (+), and HMB45 
(−). Because GCTs are not sensitive 
to chemotherapy or radiotherapy,2–4 a 
complete left pneumonectomy together 
with systemic lymphadenectomy was 
therefore performed. Pleural metas-
tasis was found during the operation, 
and therefore, GCT of this patient was 
malignant. The diagnosis of pulmonary 
GCT was identified again by postop-
erative immunohistochemistry staining 
(Fig. 2). A gene mutation profiling was 
performed by next generation sequenc-
ing (OncoScreen TM 295 genes, 
Burning Rock Dx, Guangzhou, China; 
Supplemental Table, Supplemental 
Digital Content, http://links.lww.com/
JTO/A862). The results detected seven 
mutations on five genes. No copy number 
variation or fusion/translocation events 
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Overall, the sequencing results 
indicate that the abnormalities of 
ASXL1-mediated, Notch2-mediated, 
and PARP4-mediated pathways are 
possibly involved in the disease ini-
tiation and progression of MGCT. 
Targeted therapeutics against PARP 
family (veliparib and niraparib) or 
NOTCH family (demcizumab) might 
be the promising medications; how-
ever, the clinical efficacy needs to be 
further evaluated.
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FIGURE 1.  Enhanced chest computed tomography scan showed that the tumor 
located in the left lower lobe and invaded closely to the pulmonary artery and vein.
were detected. Four out of the seven 
mutations were validated by Sanger 
sequencing, including AR, NOTCH4, 
and PARP4 (Fig. 3). However, the other 
three mutations, ASXL1 (G642 frame-
shift deletion), NOTCH2 (A3 missense 
mutation), and PARP4 (I1039 missense 
mutation) could not be validated by 
Sanger sequencing, likely because of 
their low mutation allele frequencies.
To explore the biological signifi-
cance of the mutations, we examined 
the TCGA mutation database with our 
sequencing data (Fig. 3). Both the AR 
mutation and the NOTCH4 mutation 
show a homogenous mutation pattern 
and were not reported as somatic 
mutation in all cancers. So we do not 
consider AR and Notch4 as somatic 
mutations in our case. For ASXL1, 
the frameshift deletion detected in our 
case resides on the ASXL1 mutation 
hotspot. For NOTCH2, even though the 
A3 missense mutation detected does 
not reside exactly on the most frequent 
mutation hotspot, it is right beside it. 
These mutations were reported in 
multiple cancers from TCGA data-
base. Moreover, all three mutations of 
PARP4 were also reported in TCGA 
in various cancer types but with rela-
tively low occurrence.
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FIGURE 2.  The immunohistochemistry staining results. The tumor is positive for 
S-100 and CD68, which are the specific markers of granular cell tumors.
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